Results for tag: "Bispecific Antibody Therapeutics"

The Bispecific Antibody Therapeutics market within the context of Oncology Drugs is a rapidly growing field of research and development. Bispecific antibodies are engineered to bind to two different antigens, allowing them to target and activate the immune system to fight cancer. These antibodies can be used to target both tumor cells and immune cells, allowing for more effective treatments. Bispecific antibodies have the potential to be more effective than traditional monoclonal antibodies, as they can target multiple antigens at once. Additionally, they can be used to target multiple pathways, allowing for more personalized treatments. The Bispecific Antibody Therapeutics market is expected to continue to grow as more research is conducted and new treatments are developed. Companies such as AbbVie, Amgen, AstraZeneca, and Merck are leading the way in the development of these treatments. Other companies such as Genentech, GlaxoSmithKline, and Pfizer are also investing in the research and development of bispecific antibodies. Show Less Read more